Denali Therapeutics ( (DNLI) ) just unveiled an update.
On March 5, 2025, Denali Therapeutics announced that further analyses from the Phase 2/3 HEALEY ALS Platform Trial of DNL343 did not show a treatment effect on neurofilament light, a biomarker of neuronal damage, over a 24-week period. The study, which also did not meet its primary endpoint of slowing ALS disease progression, will lead to the discontinuation of the active treatment extension. Despite these results, DNL343 was found to be safe and well tolerated, and Denali plans to explore future development opportunities for the drug.
More about Denali Therapeutics
Denali Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases.
YTD Price Performance: -23.46%
Average Trading Volume: 1,014,929
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.32B
For a thorough assessment of DNLI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com